Skip To Main Content
S. K. Barta on Muck Rack

S. K. Barta

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with S. K.

Contact S. K., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FOURTH GENERATION HUCART19‐IL18 PRODUCES DURABLE RESPONSES IN LYMPHOMA PATIENTS PREVIOUSLY RELAPSED/REFRACTORY TO ANTI‐CD19 CAR T‐CELL THERAPY

|
By J. Steven Svoboda, E. Chong, D. L. Landsburg, S. K. Barta
| Wiley Online Library Verified
Introduction: Lymphoma (NHL) patients (pts) relapsing/refractory (R/R) to anti-CD19 chimeric antigen receptor T-cells (CART) represent a challenging group in need of effective therapies. HuCART19-IL18 is a 4th generation 4-1BB CART product designed to express humanized anti-CD19 CAR and secrete interleukin 18, a pro-inflammatory cytokine shown to enhance CART efficacy in pre-clinical models.
Open in Who Shared Issue with article?

Combination of everolimus and itacitinib in patients with Hodgkin lymphoma relapsed/refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPI)

|
By J. Steven Svoboda, D. L. Landsburg, S. Nasta, S. K. Barta
| Wiley Online Library Verified
Introduction:Patients (pts) with classic Hodgkin lymphoma (cHL) who have failed or are intolerant of BV and CPI have few available treatment options. Genetic alterations in JAK/STAT pathway are frequently detected in cHL tumors making them an ideal therapeutic target.
Open in Who Shared Issue with article?

DARATUMUMAB AND EPOCH FOR HIV+/‐ PLASMABLASTIC LYMPHOMA: A FEASIBILITY STUDY OF THE AIDS MALIGNANCY CONSORTIUM (AMC 105)

|
By A. Noy, S. K. Barta, C. R. Tan, D. Kwon
| Wiley Online Library Verified
Background: Plasmablastic lymphoma (PBL) is a high-grade neoplasm with features of both lymphoma and myeloma. It was originally described primarily in people with HIV in the pre-antiretroviral era and nearly always fatal. However, a recent study of the AIDS Malignancy Consortium with EPOCH showed a 70% two-year event free survival (Ramos, Blood 2020). Currently, the majority of PBL patients do not have HIV (Ciaccio, ASH 2020).
Open in Who Shared Issue with article?
See all 3 articles